Evaluation of the Efficiency and Economic Impact of LC-OCT (Line-field Confocal Optical Coherence Tomography) for the Diagnosis and Management of Basal Cell Carcinomas

Basal Cell Carcinoma of the Skin Clinical Trial

— ECOBASO  

Official title:

Evaluation of the Efficiency and Economic Impact of LC-OCT (Line-field Confocal Optical Coherence Tomography) for the Diagnosis and Management of Basal Cell Carcinomas (ECOBASO)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06271603
• Other study ID #: 23.02645.000357-MS01
• Secondary ID: CPP Ile de Franc
• Status: Not yet recruiting
• Phase: N/A
• Start date: February 26, 2024
• Est. completion date: February 2026

Study information

• Verified date: February 2024
• Source: Damae Medical
• Contact: Philippe Saiag
• Phone: 800-555-5555
• Email: philippe.saiag[@]uvsq.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a comparative, randomized, prospective, multicenter clinical investigation aimed at evaluating the efficiency and economic impact of LC-OCT (Line-field Confocal Optical Coherence Tomography) for the diagnosis and management of basal cell carcinomas.

Description:

Basal cell carcinoma (BCC) is the most common type of skin cancer. The diagnosis and subtyping of suspicious lesions can be challenging for certain "equivocal" lesions where clinical and dermoscopic criteria do not allow for a definite diagnosis or subtyping, which determines the treatment. The most commonly used technique for the diagnosis and selection of appropriate treatment for BCC is skin biopsy. Microscopic imaging techniques allow for "optical" biopsies, which appear as an attractive alternative to traditional biopsies. The deepLive™ device integrates LC-OCT (Line-field Confocal Optical Coherence Tomography), which is a novel microscopic imaging technology with unmatched imaging performance to date, including cellular isotropic resolution (1 μm), a penetration depth of 500 μm, and the ability to obtain real-time cross-sectional and 3D images in the same orientation as histology. Numerous multicenter studies have confirmed the high performance of this technique for the diagnosis and subtyping of BCC. However, its usefulness in the diagnostic and treatment management of BCC has not been investigated prospectively. This clinical investigation is based on the hypothesis that the use of the deepLive™ device will enable diagnostic and therapeutic management by reducing the number of consultations/procedures without compromising patient outcomes compared to a traditional management approach with biopsy(ies). This strategy could optimize the entire care pathway by reducing invasive diagnostic or therapeutic procedures and freeing up dermatological resources for other procedures. This optimization of the care pathway is expected to result in a favorable economic impact on the healthcare system.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 704
• Est. completion date: February 2026
• Est. primary completion date: February 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Patient with one or more clinically suspicious lesions of BCC for which:

1. The diagnosis is uncertain following clinical and dermoscopic examination, and diagnostic biopsy is necessary according to the latest European guidelines from EADO.

2. And/or for which the knowledge of the histological subtype determines the subsequent management.

3. And/or for which diagnostic biopsy is necessary in the standard practice to confirm the clinical diagnosis (peri-orificial facial lesions, any lesion that may require complex surgical reconstruction).

Exclusion Criteria:

• The lesion is suspected to be a recurrent BCC.
• The suspicious lesion has been previously treated by other surgical or non-surgical methods (cryotherapy, topical treatment, PDT, etc.).
• Lesions within 3 cm of the eye.
• Presence of cutaneous comorbidities that could interfere with a proper evaluation of the studied lesion according to the investigator.

Related Conditions & MeSH terms

• Basal Cell Carcinoma of the Skin
• Carcinoma
• Carcinoma, Basal Cell

Intervention

Diagnostic Test:
• diagnosis based on deepLive™ LC-OCT device
Management of BCC with an initial diagnosis based on the deepLive™ device using LC-OCT technology.
• diagnosis based on skin biopsy
Control Arm: Standard management with an initial diagnosis based on skin biopsy

Locations

Country	Name	City	State
France	Hôpital Ambroise Paré	Boulogne-Billancourt

Sponsors (1)

Lead Sponsor	Collaborator
Damae Medical

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary objective is to demonstrate, at 1 year, the clinical non-inferiority and organizational and economic superiority of the management of primary BCC through diagnosis with LC-OCT compared to traditional management.	The primary objective is defined by a family of primary criteria that will be tested sequentially in a hierarchical manner. The clinical non-inferiority will be assessed by the proportion of success which is defined as the absence of residual or recurrent cancerous or precancerous lesions after 1 year of primary BCC through diagnosis with LC-OCT, as compared to traditional management.	from enrollment to the 1 year follow up
Primary	The primary objective is to demonstrate, at 1 year, the clinical non-inferiority and organizational and economic superiority of the management of primary BCC through diagnosis with LC-OCT compared to traditional management.	The primary objective is defined by a family of primary criteria that will be tested sequentially in a hierarchical manner. Organizational effectiveness will be evaluated by measuring the total time spent by dermatologists and pathologists (in hours) for managing primary BCC through diagnosis with LC-OCT, as compared to traditional management.	from enrollment to the 1 year follow up
Primary	The primary objective is to demonstrate, at 1 year, the clinical non-inferiority and organizational and economic superiority of the management of primary BCC through diagnosis with LC-OCT compared to traditional management.	The primary objective is defined by a family of primary criteria that will be tested sequentially in a hierarchical manner. Economic superiority will be assessed by comparing the total cost of management (€) of primary BCC through diagnosis with LC-OCT to traditional management.	from enrollment to the 1 year follow up
Secondary	Compare, after the diagnosis announcement and at 1 year, the quality of life of patients in the LC-OCT arm versus the standard management arm.	Quality of life will be assessed using the EQ-5D-5L questionnaire	from enrollment to the 1 year follow up
Secondary	Compare, after the diagnosis announcement and at 1 year, the anxiety levels of patients in the LC-OCT arm versus the standard management arm.	Anxiety will be assessed using a visual analog scale (score 0 - 10)	from enrollment to the 1 year follow up
Secondary	Compare patient satisfaction with their management at 1 year in the LC-OCT arm versus the standard management arm.	Patient satisfaction will be evaluated using a Likert scale focused on the overall management of the cutaneous lesion.	from enrollment to the 1 year follow up
Secondary	Evaluate the performance of LC-OCT for the diagnosis and subtyping of BCC for all patients operated on or biopsied in the LC-OCT arm.	Performance will be evaluated based on the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (PLR), negative likelihood ratio (NLR), and accuracy of LC-OCT for the diagnosis and subtyping of BCC in all patients operated on or biopsied in the LC-OCT arm, using histological diagnosis as the gold standard.	from enrollment to the 1 year follow up
Secondary	Compare dermatologists' satisfaction with patient management in the LC-OCT arm versus the standard management arm	Physician satisfaction will be evaluated using a Likert scale focused on the overall management of the cutaneous lesion.	from enrollment to the 1 year follow up
Secondary	Estimate the actual cost of conducting the diagnosis with LC-OCT technology.	Actual cost (€) of conducting the diagnosis with deepLive™ measured using micro-costing methodology	from enrollment to the 1 year follow up
Secondary	Compare healthcare consumption between the two groups at 1 year.	Typology of healthcare consumption at 1 year in each group to identify differences between the two groups in terms of: consultations, treatments, hospitalizations, medical procedures, laboratory tests, imaging, etc.	from enrollment to the 1 year follow up
Secondary	Conduct a cost-consequence analysis of patient management with LC-OCT technology versus standard management.	The descriptive cost-consequence analysis will analyze the difference in patient management costs at 1 year in relation to the impacts of deepLive™ on other clinical and organizational criteria.	from enrollment to the 1 year follow up